LA JOLLA INFECTIOUS DISEASE INSTITUTE (EIN 208965505) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2007

Legal Domicile

Principal Officer

HENRI VAN DER HEYDE

Phone

8584814198

Tax Period

2022-07-01 to 2023-06-30

LA JOLLA INFECTIOUS DISEASE INSTITUTE, founded in 2007, is a small nonprofit in the Medical Research sector that reported $517K in total revenue in fiscal year 2022. Revenue surged 135% from the prior year, signaling strong growth momentum. Expenses of $441K left a modest 15% surplus.

Mission

THE ADVANCEMENT OF SCIENCE AND FOR RESEARCH PURPOSES AS DEFINED IN SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE, INCLUDING TREATMENT, RESEARCH DESIGN AND METHODS AND KNOWLEDGE RELATED TO THE ALLERGIC RESPONSE, INFECTIOUS DISEASE AND IMMUNOLOGIC PATHWAYS.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2022)

Revenue Breakdown

Contributions & Grants $516,793

Program Service Revenue $0

Investment Income $0

Other Revenue $0

TOTAL REVENUE $516,793

Expense Breakdown

Grants Paid $0

Salaries & Benefits $325,323

Fundraising Expenses $0

Program Expenses $399,896

Other Expenses $115,655

TOTAL EXPENSES $440,978

Year-over-Year Comparison

	2022	2021	Change
Revenue	$516,793	$219,974	+1.3%
Expenses	$440,978	$432,211	+0.0%
Net Income	$75,815	$-212,237	-1.4%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

Volunteers

N/A

Governance Policies

✓ Conflict of Interest Policy

✓ Whistleblower Policy

✓ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

⚠ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$158,062

Total Directors

$158,062

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
WUN-LING CHANG MD	PRESIDENT, CEO	2.00	Officer Director	$14,304	$13,729	$28,033
HENRI VAN DER HEYDE PHD	CFO	15.00	Officer Director	$30,188	$18,858	$49,046
GEORGES E GRAU MD PHD	DIRECTOR	1.00	Director	$0	$0	$0
KENNY CHU	DIRECTOR	1.00	Director	$0	$0	$0
IRENE GRAMAGLIAPHD	SECRETARY	40.00	Officer Director	$60,791	$20,192	$80,983
ATUL PATEL	DIRECTOR	1.00	Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2023	$516,793	$440,978	$26,042	$75,815
2022	$219,974	$432,211	$7,862	$-212,237
2021	$307,799	$477,000	$24,259	$-169,201
2020	$278,057	$399,266	$39,912	$-121,209
2019	$290,954	$355,011	$11,633	$-64,057
2018	$278,939	$337,142	$72,704	$-58,203

LA JOLLA INFECTIOUS DISEASE INSTITUTE